This chronic disease primarily affects people of working age, and in addition to the social cost, it has a significant economic cost. Yet there is insufficient recognition of the condition at an EU level.
New Migraine Friendly Workplace Stamp developed by the European Migraine & Headache Alliance recognises organizations who support their employees who suffer from migraine - a severe and debilitating
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab) - read this article along with other careers information, tips and advice on BioSpace
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start